Terumo Blood and Cell Technologies (Terumo BCT) reported regulatory approvals in 14 Latin American countries for its Spectra Optia Apheresis System, allowing for new treatment options for sickle cell disease, Guillain-Barré syndrome and myasthenia gravis. This development signifies a major step toward enhancing access to therapies for patients with rare and chronic diseases in the…
This Article Is Locked, But Not Out of Reach
Jeffco BdB delivers smart insights on local businesses. Get a free account to unlock rankings, trends, and alerts tailored to you.
Curious how it works? Watch the Quickstart
Want everything unlocked? See Paid Options
Already a member? Log in here